J&J Board Changes and Officer Compensation Updates
Ticker: JNJ · Form: 8-K · Filed: 2024-09-10T00:00:00.000Z
Sentiment: neutral
Topics: governance, executive-compensation, board-of-directors
Related Tickers: JNJ
TL;DR
J&J board shake-up: Dr. JoAnn C. Smith out, Dr. Joseph M. Smith in. Officer pay details updated.
AI Summary
On September 10, 2024, Johnson & Johnson filed an 8-K report detailing changes in its board of directors and executive compensation. Specifically, the filing announced the departure of director Dr. JoAnn C. Smith and the election of new director Dr. Joseph M. Smith. Additionally, it outlined updates to the compensatory arrangements for certain officers.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — The filing primarily concerns routine corporate governance and executive compensation matters, with no immediate financial implications disclosed.
Key Players & Entities
- Johnson & Johnson (company) — Registrant
- Dr. JoAnn C. Smith (person) — Departing Director
- Dr. Joseph M. Smith (person) — Newly Elected Director
- September 10, 2024 (date) — Report Date
FAQ
Who is Dr. JoAnn C. Smith and why did she depart from the Johnson & Johnson board?
The filing states that Dr. JoAnn C. Smith departed from the board of directors of Johnson & Johnson on September 10, 2024. The specific reasons for her departure are not detailed in this 8-K filing.
What is the background of the new director, Dr. Joseph M. Smith?
The filing announces the election of Dr. Joseph M. Smith to the board of directors of Johnson & Johnson. Further details regarding his background or qualifications are not provided in this specific 8-K.
What specific changes were made to the compensatory arrangements for certain officers?
The 8-K filing indicates that there were updates to the compensatory arrangements of certain officers, but the specific details of these arrangements are not elaborated upon in this document.
What is the significance of the 'Departure of Directors or Certain Officers' item in this filing?
This item signifies that there have been changes in the company's leadership, specifically the departure of a director and the election of a new one, which is a mandatory disclosure for public companies.
Are there any financial implications mentioned regarding the board changes or compensation updates?
This 8-K filing does not explicitly mention any immediate financial implications stemming from the director changes or the updates to officer compensation arrangements.
From the Filing
0000200406-24-000081.txt : 20240910 0000200406-24-000081.hdr.sgml : 20240910 20240910162610 ACCESSION NUMBER: 0000200406-24-000081 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240910 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20240910 DATE AS OF CHANGE: 20240910 FILER: COMPANY DATA: COMPANY CONFORMED NAME: JOHNSON & JOHNSON CENTRAL INDEX KEY: 0000200406 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 221024240 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1229 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-03215 FILM NUMBER: 241290376 BUSINESS ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 BUSINESS PHONE: 732-524-2455 MAIL ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 8-K 1 jnj-20240910.htm 8-K jnj-20240910 0000200406 false 0000200406 2024-09-10 2024-09-10 0000200406 us-gaap:CommonStockMember 2024-09-10 2024-09-10 0000200406 jnj:A5.50NotesDue2024Member 2024-09-10 2024-09-10 0000200406 jnj:A1.150NotesDueNovember2028Member 2024-09-10 2024-09-10 0000200406 jnj:A3.20NotesDueNovember2032Member 2024-09-10 2024-09-10 0000200406 jnj:A1.650NotesDue2035Member 2024-09-10 2024-09-10 0000200406 jnj:A3.350NotesDueNovember2036Member 2024-09-10 2024-09-10 0000200406 jnj:A3.550NotesDueNovember2044Member 2024-09-10 2024-09-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM  8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported):  September 10, 2024 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) One Johnson & Johnson Plaza , New Brunswick , New Jersey    08933   (Address of Principal Executive Offices)  (Zip Code)  Registrant's telephone number, including area code: 732 - 524-0400 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, Par Value $1.00 JNJ New York Stock Exchange 5.50% Notes Due November 2024 JNJ24BP New York Stock Exchange 1.150% Notes Due November 2028 JNJ28 New York Stock Exchange 3.20% Notes Due November 2032 JNJ32 New York Stock Exchange 1.650% Notes Due May 2035 JNJ35 New York Stock Exchange 3.350% Notes Due November 2036 JNJ36A New York Stock Exchange 3.550% Notes Due November 2044 JNJ44 New York Stock Exchange Item 5.02 Departure of Directo